Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Expands GI Warnings For Junior Strength Advil, Orudis KT Labeling

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare will revise labeling for two of its analgesic products to include more explicit warnings following FDA approval on Aug. 30

You may also be interested in...



FDA, NCL Launch “Take With Care” OTC Analgesic Safety Campaign

FDA is "very seriously" looking into labeling changes for OTC pain relievers, according to outgoing Associate Commissioner for External Relations Peter Pitts

Aspirin, NSAID GI Bleeding Language Could Replace Alcohol Warning

Warnings detailing the risk of gastrointestinal bleeding with use of aspirin and other non-steroidal anti-inflammatory drugs should replace the current alcohol warning on such products, NDAC members asserted during a meeting in Silver Spring, Md. Sept. 20

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel